Search results
Results from the WOW.Com Content Network
The buyout talks involving Acadia underscore the renewed interest by private equity firms in the sector, following U.S. legislative reforms that expanded insurance coverage for behavioral health ...
Mere rumors that a biotech stock could get bought out can send shares surging. Chances are that a few biotech companies will be scooped up by larger players over. Buyout! The word gets biotech ...
Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009. [ 5 ] [ 6 ] [ 7 ] Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia -related psychosis, [ 8 ] major depressive disorder , [ 9 ] schizophrenia ...
Acadia's drug, trofinetide, to treat Rett syndrome, a genetic brain disorder, was launched in the U.S. last year under the brand name Daybue. "Acadia has misrepresented Daybue's safety profile ...
Valeant Pharmaceuticals: Allergan, Inc: 45 58 Valeant Pharmaceuticals and activist investor Bill Ackman offered to buy Botox maker Allergan, proposing a cash-and-stock deal worth about $152.89. [31] 20 2014 Monsanto Company Inc. Syngenta AG: 40 51 Monsanto weighed $40 billion unsolicited bid for Swiss rival, Syngenta aiming to avoid US ...
According to research firm Modern Healthcare's M&A Watch Report, there were a whopping 172 pharmaceutical, life sciences, and biotechnology mergers and acquisitions over the previous three quarters.
After suffering rejection from the FDA in April, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is making another bid to expand the scope of its Parkinson's disease med Nuplazid. Acadia plans to ...
For premium support please call: 800-290-4726 more ways to reach us